Combination of Chinese Herbal Medicines and Conventional Treatment versus Conventional Treatment Alone in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention (5C Trial): An Open-Label Randomized Controlled, Multicenter Study
Table 1
Baseline characteristics of participants.
Characteristic
Treatment group
Control group
()
()
Demographics
Male, (%)
322 (79.7)
281 (69.6)
Age, median (interquartile ranges)
60 (53, 67.75)
61 (53, 68)
Final diagnosis‡, (%)
NSTE-ACS
287 (71.0)
296 (73.3)
STE-ACS
117 (29.0)
108 (26.7)
Number of diseased vessels, (%)
One
104 (25.7)
110 (27.2)
Two
131 (32.4)
115 (28.5)
Three
169 (41.8)
179 (44.3)
Target vessel, (%)
LAD
322 (79.7)
319 (79.0)
LCX
226 (55.9)
209 (51.7)
RCA
231 (57.2)
234 (57.9)
LM
30 (7.4)
36 (8.9)
Risk factors, (%)
Hypertension
247 (61.1)
262 (64.9)
Diabetes mellitus
111 (27.5)
123 (30.4)
Hyperlipidemia
163 (40.3)
159 (39.4)
Smoking history
234 (57.9)
225 (55.7)
Family history of CAD
103 (25.5)
95 (23.5)
BMI** mean (SD)
25.31 (3.01)
25.60 (2.88)
Medication, (%)
Beta-blocker
157 (38.9)
160 (39.6)
ACEI
125 (30.9)
123 (30.4)
ARB
74 (18.3)
80 (19.8)
CCB
96 (23.8)
102 (25.2)
Statin
195 (48.3)
192 (47.5)
‡NSTE-ACS: non-ST-segment elevation ACS; STE-ACS: ST-segment elevation ACS. LAD: left anterior descending artery; LCX: left circumflex artery; RCA: right coronary artery; LM: left main coronary artery.
**BMI: body mass index (kg/m2).
